Lixte Biotechnology (LIXT)

• Market cap: $39.2M
• 1 day: -3.71%
• 5 days: -8.92%
• 1 month: 9.77%
• 3 months: -5.34%
• 6 months: -23.93%
• Year to date: -12.24%
• 1 year: 167.46%
• 5 years: -86.99%
• 10 years: -90.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.

Employees: 3